Patents by Inventor Neelima Khairatkar-Joshi

Neelima Khairatkar-Joshi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12064442
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: August 20, 2024
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Publication number: 20240156840
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Application
    Filed: December 21, 2023
    Publication date: May 16, 2024
    Inventors: Neelima KHAIRATKAR-JOSHI, Abhay KULKARNI, Dinesh Pradeep WALE, Vikram M. BHOSALE, Piyush AGARWAL, Patrick KEOHANE, Sudeesh K. TANTRY, Chad OH
  • Publication number: 20230285689
    Abstract: A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.
    Type: Application
    Filed: May 1, 2023
    Publication date: September 14, 2023
    Inventors: Ulhas R. DHUPPAD, Ashok KATKURWAR, Yashwant GUPTA, Rajesh ANKAM, Chandrakant DHATRAK, Neelima KHAIRATKAR-JOSHI, Abhay KULKARNI, Dinesh Pradeep WALE, Vikram Mansingh BHOSALE, Piyush AGARWAL, Patrick KEOHANE, Sudeesh K. TANTRY, Chad OH
  • Patent number: 11679210
    Abstract: A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 20, 2023
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak, Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram Mansingh Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Publication number: 20230000872
    Abstract: The present patent application relates to a transient receptor potential ankyrin-1 (“TRPA1”) antagonist for the treatment of neuropathic pain in a subject. Particularly, the present patent application relates to a method of treating neuropathic pain in a subject in need thereof by orally administering to the subject a thienopyrimidinedione Compound as a TRPA1 antagonist. The present invention also relates to a pharmaceutical composition comprising the TRPA1 antagonist, and a process for preparing such a pharmaceutical composition.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 5, 2023
    Inventors: Neelima Khairatkar-Joshi, Monika Tandon, Girish Gudi, Patrick Keohane, Zona Godsafe
  • Publication number: 20220387452
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Application
    Filed: June 17, 2022
    Publication date: December 8, 2022
    Inventors: Neelima KHAIRATKAR-JOSHI, Abhay KULKARNI, Dinesh Pradeep WALE, Vikram M. BHOSALE, Piyush AGARWAL, Patrick KEOHANE, Sudeesh K. TANTRY, Chad OH
  • Patent number: 11400101
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: August 2, 2022
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Publication number: 20210220574
    Abstract: A nasal dispensing device and pharmaceutical composition includes a container; a dispenser head having at least a pump, a dispensing channel, and a dispensing orifice; a dip tube; and a pharmaceutical composition comprising mometasone, an ester thereof (e.g., mometasone furoate), or a salt thereof and olopatadine or its salt (e.g., olopatadine hydrochloride). The container can have a conically shaped internal bottom, angled downwardly toward a center, and a further angularly deepened well, centrally located, with the dip tube extending into the well. An optional cap is provided that includes a sealing sleeve communicating in a seal tight manner with a perimeter of a lateral wall of the dispenser head.
    Type: Application
    Filed: June 28, 2018
    Publication date: July 22, 2021
    Inventors: Ulhas R. Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak, Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram Mansignh Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Patent number: 10988467
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 27, 2021
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai
  • Publication number: 20210077506
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Application
    Filed: August 26, 2020
    Publication date: March 18, 2021
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Pradeep D. Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Patent number: 10821100
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: November 3, 2020
    Assignee: Ichnos Sciences SA
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Patent number: 10758550
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: September 1, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Pradeep D. Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Patent number: 10758517
    Abstract: The present invention relates to a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor for the treatment of osteoarthritis pain in a subject. For example, the present invention relates to a method of treating moderate osteoarthritis pain in a subject in need thereof by orally administering to the subject a substituted triazolone compound as a mPGES-1 inhibitor. The present invention also relates to pharmaceutical compositions comprising the mPGES-1 inhibitor, and to processes for preparing such pharmaceutical compositions.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: September 1, 2020
    Assignee: ICHNOS SCIENCES SA
    Inventors: Monika Tandon, Sumit Sant, Neelima Khairatkar-Joshi, Girish Gudi, Vinu C. A. Menon, Ravi Talluri
  • Publication number: 20200247800
    Abstract: The present application relates to substituted fused heteroaryl and hetero-cyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase.
    Type: Application
    Filed: May 4, 2018
    Publication date: August 6, 2020
    Inventors: Sukeerthi Kumar, Abraham Thomas, Sachin Sundarlal Chaudhari, Laxmikant Atmaram Gharat, Neelima Khairatkar-Joshi, Daisy Manish Shah, Indranil Mukhopadhyay
  • Patent number: 10653661
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 19, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram M. Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Patent number: 10646500
    Abstract: The present patent application relates to a method of treating allergic rhinitis in a subject (preferably a human) by administering a combination of mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: May 12, 2020
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram Mansingh Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Patent number: 10548907
    Abstract: The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 4, 2020
    Assignee: Glenmark Specialty S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Dinesh Pradeep Wale, Vikram Mansingh Bhosale, Piyush Agarwal, Patrick Keohane, Sudeesh K. Tantry, Chad Oh
  • Publication number: 20190282548
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Application
    Filed: May 28, 2019
    Publication date: September 19, 2019
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Patent number: 10391083
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: August 27, 2019
    Assignee: GLENMARK PHARMACEUTICALS S.A
    Inventors: Laxmikant A. Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya G. Kattige
  • Publication number: 20190256508
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR?t). These compounds prevent, inhibit, or suppress the action of ROR?t and are therefore useful in the treatment of ROR?t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Inventors: Sanjib Das, Laxmikant A. Gharat, Rajendra L. Harde, Sandeep Y. Shelke, Shailesh R. Pardeshi, Abraham Thomas, Neelima Khairatkar-Joshi, Daisy M. Shah, Malini Bajpai